Takeda Pharmaceutical Company Limited TKPYY and Natrogen
Therapeutics International, Inc. (“Natrogen”) jointly announced today an
agreement whereby Takeda will acquire an exclusive license to develop
Natrogen's Natura-alpha compound as well as an option to acquire
Natrogen. Natura-alpha is a synthetic small molecule oral compound that
is believed to inhibit pro-inflammatory cytokine expression, which may
help to reduce gastrointestinal inflammation. Natura-alpha is currently
in Phase 2 development for the treatment of ulcerative colitis (UC).
“Today's announcement reinforces Takeda's continued commitment toward
addressing the needs of patients with gastrointestinal diseases,” said
Asit Parikh, M.D., Ph.D., vice president, general medicine, Takeda.
“Natura-alpha is a strategic fit with our gastrointestinal portfolio,
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in